240 related articles for article (PubMed ID: 28337527)
1. Phase II study of the c-MET inhibitor tivantinib (ARQ 197) in patients with relapsed or relapsed/refractory multiple myeloma.
Baljevic M; Zaman S; Baladandayuthapani V; Lin YH; de Partovi CM; Berkova Z; Amini B; Thomas SK; Shah JJ; Weber DM; Fu M; Cleeland CS; Wang XS; Stellrecht CM; Davis RE; Gandhi V; Orlowski RZ
Ann Hematol; 2017 Jun; 96(6):977-985. PubMed ID: 28337527
[TBL] [Abstract][Full Text] [Related]
2. A phase I dose-escalation study of Tivantinib (ARQ 197) in adult patients with metastatic solid tumors.
Rosen LS; Senzer N; Mekhail T; Ganapathi R; Chai F; Savage RE; Waghorne C; Abbadessa G; Schwartz B; Dreicer R
Clin Cancer Res; 2011 Dec; 17(24):7754-64. PubMed ID: 21976535
[TBL] [Abstract][Full Text] [Related]
3. Phase II study of tivantinib (ARQ 197) in patients with metastatic triple-negative breast cancer.
Tolaney SM; Tan S; Guo H; Barry W; Van Allen E; Wagle N; Brock J; Larrabee K; Paweletz C; Ivanova E; Janne P; Overmoyer B; Wright JJ; Shapiro GI; Winer EP; Krop IE
Invest New Drugs; 2015 Oct; 33(5):1108-14. PubMed ID: 26123926
[TBL] [Abstract][Full Text] [Related]
4. A phase 2 multicenter study of tivantinib (ARQ 197) monotherapy in patients with relapsed or refractory germ cell tumors.
Feldman DR; Einhorn LH; Quinn DI; Loriot Y; Joffe JK; Vaughn DJ; Fléchon A; Hajdenberg J; Halim AB; Zahir H; Motzer RJ
Invest New Drugs; 2013 Aug; 31(4):1016-22. PubMed ID: 23417696
[TBL] [Abstract][Full Text] [Related]
5. A phase I study of tivantinib in combination with temsirolimus in patients with advanced solid tumors.
Kyriakopoulos CE; Braden AM; Kolesar JM; Eickhoff JC; Bailey HH; Heideman J; Liu G; Wisinski KB
Invest New Drugs; 2017 Jun; 35(3):290-297. PubMed ID: 28004284
[TBL] [Abstract][Full Text] [Related]
6. Targeting the pro-survival protein MET with tivantinib (ARQ 197) inhibits growth of multiple myeloma cells.
Zaman S; Shentu S; Yang J; He J; Orlowski RZ; Stellrecht CM; Gandhi V
Neoplasia; 2015 Mar; 17(3):289-300. PubMed ID: 25810013
[TBL] [Abstract][Full Text] [Related]
7. A phase II trial of a selective c-Met inhibitor tivantinib (ARQ 197) monotherapy as a second- or third-line therapy in the patients with metastatic gastric cancer.
Kang YK; Muro K; Ryu MH; Yasui H; Nishina T; Ryoo BY; Kamiya Y; Akinaga S; Boku N
Invest New Drugs; 2014 Apr; 32(2):355-61. PubMed ID: 24337769
[TBL] [Abstract][Full Text] [Related]
8. Phase I trial of a selective c-MET inhibitor ARQ 197 incorporating proof of mechanism pharmacodynamic studies.
Yap TA; Olmos D; Brunetto AT; Tunariu N; Barriuso J; Riisnaes R; Pope L; Clark J; Futreal A; Germuska M; Collins D; deSouza NM; Leach MO; Savage RE; Waghorne C; Chai F; Garmey E; Schwartz B; Kaye SB; de Bono JS
J Clin Oncol; 2011 Apr; 29(10):1271-9. PubMed ID: 21383285
[TBL] [Abstract][Full Text] [Related]
9. Selective Inhibitor of the c-Met Receptor Tyrosine Kinase in Advanced Hepatocellular Carcinoma: No Beneficial Effect With the Use of Tivantinib?
Zhao S; Wu W; Jiang H; Ma L; Pan C; Jin C; Mo J; Wang L; Wang K
Front Immunol; 2021; 12():731527. PubMed ID: 34804015
[TBL] [Abstract][Full Text] [Related]
10. A phase 1 study of the c-Met inhibitor, tivantinib (ARQ197) in children with relapsed or refractory solid tumors: A Children's Oncology Group study phase 1 and pilot consortium trial (ADVL1111).
Geller JI; Perentesis JP; Liu X; Minard CG; Kudgus RA; Reid JM; Fox E; Blaney SM; Weigel BJ
Pediatr Blood Cancer; 2017 Nov; 64(11):. PubMed ID: 28449393
[TBL] [Abstract][Full Text] [Related]
11. Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 study.
Santoro A; Rimassa L; Borbath I; Daniele B; Salvagni S; Van Laethem JL; Van Vlierberghe H; Trojan J; Kolligs FT; Weiss A; Miles S; Gasbarrini A; Lencioni M; Cicalese L; Sherman M; Gridelli C; Buggisch P; Gerken G; Schmid RM; Boni C; Personeni N; Hassoun Z; Abbadessa G; Schwartz B; Von Roemeling R; Lamar ME; Chen Y; Porta C
Lancet Oncol; 2013 Jan; 14(1):55-63. PubMed ID: 23182627
[TBL] [Abstract][Full Text] [Related]
12. A Phase II Study of the c-Met Inhibitor Tivantinib in Combination with FOLFOX for the Treatment of Patients with Previously Untreated Metastatic Adenocarcinoma of the Distal Esophagus, Gastroesophageal Junction, or Stomach.
Pant S; Patel M; Kurkjian C; Hemphill B; Flores M; Thompson D; Bendell J
Cancer Invest; 2017 Aug; 35(7):463-472. PubMed ID: 28662341
[TBL] [Abstract][Full Text] [Related]
13. Tivantinib (ARQ 197), a selective inhibitor of MET, in patients with microphthalmia transcription factor-associated tumors: results of a multicenter phase 2 trial.
Wagner AJ; Goldberg JM; Dubois SG; Choy E; Rosen L; Pappo A; Geller J; Judson I; Hogg D; Senzer N; Davis IJ; Chai F; Waghorne C; Schwartz B; Demetri GD
Cancer; 2012 Dec; 118(23):5894-902. PubMed ID: 22605650
[TBL] [Abstract][Full Text] [Related]
14. Phase 1 dose-escalation trial evaluating the combination of the selective MET (mesenchymal-epithelial transition factor) inhibitor tivantinib (ARQ 197) plus erlotinib.
Goldman JW; Laux I; Chai F; Savage RE; Ferrari D; Garmey EG; Just RG; Rosen LS
Cancer; 2012 Dec; 118(23):5903-11. PubMed ID: 22605616
[TBL] [Abstract][Full Text] [Related]
15. Phase II Study of Tivantinib and Cetuximab in Patients With KRAS Wild-type Metastatic Colorectal Cancer With Acquired Resistance to EGFR Inhibitors and Emergence of MET Overexpression: Lesson Learned for Future Trials With EGFR/MET Dual Inhibition.
Rimassa L; Bozzarelli S; Pietrantonio F; Cordio S; Lonardi S; Toppo L; Zaniboni A; Bordonaro R; Di Bartolomeo M; Tomasello G; Dadduzio V; Tronconi MC; Piombo C; Giordano L; Gloghini A; Di Tommaso L; Santoro A
Clin Colorectal Cancer; 2019 Jun; 18(2):125-132.e2. PubMed ID: 30846365
[TBL] [Abstract][Full Text] [Related]
16. A randomized, double-blind, placebo-controlled, phase III trial of erlotinib with or without a c-Met inhibitor tivantinib (ARQ 197) in Asian patients with previously treated stage IIIB/IV nonsquamous nonsmall-cell lung cancer harboring wild-type epidermal growth factor receptor (ATTENTION study).
Yoshioka H; Azuma K; Yamamoto N; Takahashi T; Nishio M; Katakami N; Ahn MJ; Hirashima T; Maemondo M; Kim SW; Kurosaki M; Akinaga S; Park K; Tsai CM; Tamura T; Mitsudomi T; Nakagawa K
Ann Oncol; 2015 Oct; 26(10):2066-72. PubMed ID: 26153496
[TBL] [Abstract][Full Text] [Related]
17. Combination therapy with pazopanib and tivantinib modulates VEGF and c-MET levels in refractory advanced solid tumors.
Kummar S; Srivastava AK; Navas T; Cecchi F; Lee YH; Bottaro DP; Park SR; Do KT; Jeong W; Johnson BC; Voth AR; Rubinstein L; Wright JJ; Parchment RE; Doroshow JH; Chen AP
Invest New Drugs; 2021 Dec; 39(6):1577-1586. PubMed ID: 34180036
[TBL] [Abstract][Full Text] [Related]
18. A phase I dose escalation study of oral c-MET inhibitor tivantinib (ARQ 197) in combination with gemcitabine in patients with solid tumors.
Pant S; Saleh M; Bendell J; Infante JR; Jones S; Kurkjian CD; Moore KM; Kazakin J; Abbadessa G; Wang Y; Chen Y; Schwartz B; Camacho LH
Ann Oncol; 2014 Jul; 25(7):1416-1421. PubMed ID: 24737778
[TBL] [Abstract][Full Text] [Related]
19. A Phase-1b study of tivantinib (ARQ 197) in adult patients with hepatocellular carcinoma and cirrhosis.
Santoro A; Simonelli M; Rodriguez-Lope C; Zucali P; Camacho LH; Granito A; Senzer N; Rimassa L; Abbadessa G; Schwartz B; Lamar M; Savage RE; Bruix J
Br J Cancer; 2013 Jan; 108(1):21-4. PubMed ID: 23287988
[TBL] [Abstract][Full Text] [Related]
20. ARQ-197, a small-molecule inhibitor of c-Met, reduces tumour burden and prevents myeloma-induced bone disease in vivo.
Lath DL; Buckle CH; Evans HR; Fisher M; Down JM; Lawson MA; Chantry AD
PLoS One; 2018; 13(6):e0199517. PubMed ID: 29924867
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
